<DOC>
	<DOCNO>NCT00572806</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate use insulin aspart start therapy improve efficacy daytime blood glucose cycle profile subject type 2 diabetes .</brief_summary>
	<brief_title>Initiation Insulin Aspart Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes least 3 year HbA1c great 8.0 % Body Mass Index ( BMI ) 40.0 kg/m2 Inadequate treatment diet OADs Never receive treatment insulin Type 1 diabetes Known suspected allergy investigational product</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>